CD274 and ovarian carcinoma: When ovarian cancer with normal homologous recombination repair mechanism is treated with PARP inhibitors or platinum drugs, both the pathway of immune activation (neoantigen production due to repair errors and Interferon (IFN) response) and the pathway of immunosuppression through elevated PD-L1 expression are functional due to the normal homologous recombination repair mechanism [34].